Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    viravaxx
Previous Study | Return to List | Next Study

Study to Evaluate Induction of HBV Virus Neutralizing Antibodies Using VVX001

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03625934
Recruitment Status : Unknown
Verified August 2018 by Viravaxx AG.
Recruitment status was:  Recruiting
First Posted : August 10, 2018
Last Update Posted : August 10, 2018
Sponsor:
Collaborators:
Gouya Insights
KKS MedUni Vienna
Information provided by (Responsible Party):
Viravaxx AG

Brief Summary:

The Study will evaluate the effects of VVX001, a novel vaccine for hepatitis B, to

  • elicit a robust protective IgG immune response in vaccine naive subjects
  • in subjects who failed to demonstrate seroconversion after treatment with a licensed hepatitis B vaccine and
  • in patients chronically infected with HBV.

Condition or disease Intervention/treatment Phase
Hepatitis B Biological: VVX001 Biological: Placebo Phase 1 Phase 2

Detailed Description:
VVX001 is a recombinant fusion Protein composed of PreS from the large surface antigen of HBV and Peptides derived from the grass pollen allergen Phl p 5. In a previous trial in allergic but otherwise healthy subjects the product has been shown to elicit a potent IgG response to the epitope of PreS1, which is responsible for binding to the cellular receptor NTCP. These antibodies prevent infection with HBV in a cell culture model. The present study will evaluate if such an immune response can also be achieved in four different patient populations: 1) vaccine naive subjects; 2) subjects having failed to seroconvert upon vaccination with a licensed HBV vaccine; 3) patients who are chronically infected with HBV, but are classified as inactive carriers; 4) patients with active chronic HBV infection who are HbEAg negative and chronically treated with nucleo(t)side (NUC) antiviral drugs. All subjects will receive 5 s.c. injections of VVX001, the time course of antibody response to PreS1 will be monitored in all of them. In cohort 4) NUC treatment will be withdrawn at different timepoints during the study and the effect of treatment with VVX001 on hepatitis B disease Parameters will be monitored. Subjects will be followed for 6 months after the of treatment for Evaluation of a long-term effect.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Study to Evaluate the Induction of HBV Virus Neutralizing Antibodies in Healthy Vaccine Naive Adults and Non-responders and in Patients Chronically Infected With HBV Using VVX001
Actual Study Start Date : August 6, 2018
Estimated Primary Completion Date : August 31, 2020
Estimated Study Completion Date : December 20, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: VVX001 (20 micrograms)
Subjects will receive 5 injections of 20 micrograms each over a period of 4 months
Biological: VVX001
5 s.c. injections of 20 micrograms of VVX001 four weeks apart

Placebo Comparator: Placebo
Subjects will receive 5 s.c. injections of matching placebo over a period of 4 months
Biological: Placebo
5 s.c. injections of matching Placebo four weeks apart




Primary Outcome Measures :
  1. PreS specific IgG antibodies [ Time Frame: 4 weeks after the last injection of study drug ]
    Titer of PreS specific IgG antibodies


Secondary Outcome Measures :
  1. PreS specific IgG, IgG1 and IgG4 antibodies [ Time Frame: 4 weeks and 6 months after the last injection of study drug ]
    Titers of PreS specific IgG, IgG1 and IgG4 antibodies

  2. HbSAg specific antibodies [ Time Frame: 4 weeks and 6 months after the last injection of study drug ]
    Titers of HbSAg specific antibodies

  3. Suppression of HBV infection [ Time Frame: 4 weeks and 6 months after the last injection of study drug ]
    Suppression of HBV infection in HepG2-NTCP cells using HBV strain D3 in cell culture with patient sera

  4. T cell proliferation [ Time Frame: 4 weeks and 6 months after the last injection of study drug ]
    Proliferation of PreS specific CD4 and CD8 T cells

  5. HbSAg titers [ Time Frame: 4 weeks and 6 months after the last injection of study drug ]
    HbS Antigen titers will be measured in chronically infected patients

  6. HBV DNA load [ Time Frame: 4 weeks and 6 months after the last injection of study drug ]
    HBV DNA load will be measured by PCR in chronically infected patients

  7. HBVcrAg titers [ Time Frame: 4 weeks and 6 months after the last injection of study drug ]
    HBVcrAG titers will be measured in chronically infected patients


Other Outcome Measures:
  1. Adverse events [ Time Frame: up to 52 weeks ]
    Frequency, intensity and relatedness of adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Cohort 1: hepatits B vaccine naive subjects Seronegative for anti-HBs and anti-HBc antibodies and for HBs Antigen
  • Cohort 2: Subjects who failed to develop a protective immune response upon standard vaccination with a licensed hepatitis B vaccine (<10 IU/L anti HbS antibodies) Seronegative for anti-HbS (<10 IU/L) and anti-HBc antibodies and for HbSAg
  • Cohort 3: Parameters confirmed at screening during the past 12 months

    1. HBeAg negative;
    2. HbSAg positive at screening <3000 IU/ml;
    3. HBV viral load <2000 IU/ml
    4. ALT Levels ≤ULN at screening
  • Cohort 4a: Parameters confirmed at screening during the last 12 months

    1. HBeAg negative;
    2. HbSAg positive <1000 IU/ml
    3. HBV DNA not detectable for at least 2 years
    4. History of nucleos(t)die Treatment for at least 3 years
    5. Willingness to discontinue NUC treatment during study
    6. ALT levels ≤ULN at screening
  • Cohort 4b: in addition to cohort 4a:

    1. willingness to discontinue NUC treatment 6 weeks before entering the Study
    2. ALT Levels ≤ULN 6 weeks before entering the study and

      • 5x ULN at screening

Exclusion Criteria:

  • Pregnant or breast-feeding females, adequate contraception required during the treatment phase
  • History of grass pollen allergy
  • Co-infection with HCV, HDV, HIV
  • History of auto-immune hepatitis
  • Elevated Levels of Alpha-Fetoprotein (AFP) >100 ng/ml
  • Documented history of decompensated liver disease (albumin <3.5 g/dl and bilirubin >1.3 mg/dl)
  • Autoimmune disorders, transplant recipients, use of immunosuppressive or immune modulating agents
  • Oral corticosteroids of 20 mg/week within the past 4 weeks prior to screening
  • History of treatment with PEG-IFN of IFN for at least 1 year prior to screening
  • History of evidence or conditions associated with chronic liver disease
  • Acute fever at time of enrolment
  • History of alcohol abuse
  • Planned administration of a vaccine not foreseen by study protocol in the period starting 30 days before first product administration and during the entire study period with exception of influenza vaccine
  • History of Cancer
  • Other severe co-morbid conditions and concurrent medication making the subject unsuitable for participation
  • blood or plasma donation within 1 month of study enrolement and during the course of the study
  • For all patients with chronic HBV infection:

    1. Total bilirubin >2x ULN confirmed by repeat testing within 2 weeks, unless historical documentation of Gilbert's syndrome
    2. Documented or suspected hepatocelluar carcinoma
    3. Presence of cholangitis, cholecystitis or bile duct obstruction
    4. Liver cirrhosis assessed by fibroscan with elastography <9kPa within the previous 12 months and FIB-score <3.2 at study entry

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03625934


Contacts
Layout table for location contacts
Contact: Rainer Henning, PhD +4317966296 ext 114 r.henning@viravaxx.com
Contact: Ghazaleh Gouya, MD +436504704206 gouya@gouya-insights.com

Locations
Layout table for location information
Austria
Medical University of Vienna Recruiting
Vienna, Austria, 1090
Contact: Ursula Wiedermann, MD    +431 40160 38290    ursula.wiedermann@meduniwien.ac.at   
Contact: Petra Munda, MD    +43 1 40400 4741    petra.munda@meduniwien.ac.at   
Sponsors and Collaborators
Viravaxx AG
Gouya Insights
KKS MedUni Vienna
Investigators
Layout table for investigator information
Principal Investigator: Petra Munda, MD Medical University Vienna
Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: Viravaxx AG
ClinicalTrials.gov Identifier: NCT03625934    
Other Study ID Numbers: VVX001-CS001
First Posted: August 10, 2018    Key Record Dates
Last Update Posted: August 10, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis B
Hepatitis
Liver Diseases
Digestive System Diseases
Hepadnaviridae Infections
DNA Virus Infections
Virus Diseases
Hepatitis, Viral, Human